Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 1, 2012, Pages 12-20

  Singla, Sandeep ^a   Karam, Pascal ^a   Deshmukh, Abhishek J ^a   Mehta, Jawahar ^a   Paydak, Hakan ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

antiarrhythmic; atrial fibrillation; cardiac pharmacology; heart disease

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DOFETILIDE; DRONEDARONE; FLECAINIDE; MORACIZINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RANOLAZINE; SOTALOL; VERNAKALANT;

CATHETER ABLATION; DISEASE CONTROL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HEART RATE; HUMANS; SINOATRIAL NODE;

EID: 84856970339     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410397195     Document Type: Review

References (70)

1. -2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006 ; 114 (7). e257 - e354
2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 ; 114 (2). 119-125 (Pubitemid 44420743)
3. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 ; 347 (23). 1825-1833 (Pubitemid 35417773)
4. Van Gelder IC, Hagens VE, Bokser HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002 ; 347 (23). 1834-1840 (Pubitemid 35417774)
5. Hohnloser SH, Kuck KH, Lilienthal J.. Rhythm or rate control in atrial fibrillation-pharmacological interventions in atrial fibrillation (PIAF). Lancet. 2000 ; 356 (9244). 1789-1794
6. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) Study. J Am Coll Cardiol. 2003 ; 41 (10). 1690-1696 (Pubitemid 36584236)
7. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs. rhythm control in patients with non valvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004 ; 126(2): 476-486 (Pubitemid 39093433)
8. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D.. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998 ; 98 (10). 946-952 (Pubitemid 28446646)
9. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of left ventricular dysfunction. J Am Coll Cardiol. 1998 ; 32 (3). 695-703 (Pubitemid 28435256)
10. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE.. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995 ; 98 (5). 476-484
11. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003 ; 42 (2). 185-197 (Pubitemid 36851403)
12. Reiffel JA.. A contemporary look at classic trials in atrial fibrillation: What do they really show and how might they apply to future therapies?. Am J Cardiol. 2008 ; 102 (6A). 3H - 11H
13. Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the atrial fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004 ; 109 (16). 1973-1980 (Pubitemid 38552376)
14. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004 ; 109 (12). 1509-1513 (Pubitemid 38420179)
15. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005 ; 352 (18). 1861-1872
16. Van Gelder IC, Crijns HJ, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol. 1993 ; 72 (7). 560-566 (Pubitemid 23259451)
17. Viswanathan K, Daniak SM, Salomone K, et al. Effect of cardioversion of atrial fibrillation on improvement in left ventricular performance. Am J Cardiol. 2001 ; 88 (4). 439-441 (Pubitemid 32823314)
18. Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004 ; 351 (23). 2373-2383
19. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs. antiarrhythmic drugs as first line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005 ; 293 (21). 2634-2640 (Pubitemid 40744248)
20. Purerfellner H, Martinek M, Aichinger J, Nesser HJ, Kempen K, Janssen JP.. Quality of life restored to normal in patients with atrial fibrillation after pulmonary vein ostial isolation. Am Heart J. 2004 ; 148 (2). 318-325 (Pubitemid 39099230)
21. Manning WJ, Leeman DE, Gotch PJ, Come PC.. Pulsed doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol. 1989 ; 13 (3). 617-623 (Pubitemid 19073928)
22. Therkelsen SK, Groenning BA, Svendsen JH, Jensen GB.. Atrial and ventricular volume and function evaluated by magnetic resonance imaging in patients with persistent atrial fibrillation before and after cardioversion. Am J Cardiol. 2006 ; 97 (8). 1213-1219
23. Khan IA.. Pharmacological cardioversion of recent onset atrial fibrillation. Eur Heart J. 2004 ; 25 (15). 1274-1276 (Pubitemid 38998501)
24. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008 ; 358 (25). 2667-2677 (Pubitemid 351860859)
25. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999 ; 341 (12). 857-865 (Pubitemid 29427047)
26. Josephson MA, Ikeda N, Singh BN.. Effects of flecainide on ventricular function: clinical and experimental 20. correlations. Am J Cardiol. 1984 ; 53 (5). 95B - 100B (Pubitemid 14193848)
27. Hellerstrand KH, Nathan AW, Bexton RS, Camm AJ.. Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds. Am J Cardiol. 1984 ; 53 (5). 30B - 38B (Pubitemid 14193840)
28. Morganroth J, Horowitz LN.. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol. 1984 ; 53 (5). 89B - 94B (Pubitemid 14193847)
29. Roden DM. Goodman & Gilman's Pharmacology. 11 e ed. Chicago, IL: McGraw Hill; 2006. Brunton LL Lazo JS Parker KL, ed. Chicago, IL: McGraw Hill ; 2006 :
30. Feld GK, Chen PS, Nicod P, et al. Possible atrial proarrhythmic effects of class IC agents. Am J Cardiol. 1990 ; 66(3): 378-383 (Pubitemid 20235770)
31. Morganroth J, Anderson JL, Gentzkow GP.. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol. 1986 ; 8 (3). 607-615 (Pubitemid 16048014)
32. Pritchett ELC, Wilkinson WE.. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol. 1991 ; 67 (11). 976-980
33. Falk RH, Fogel RI.. Flecainide. J Cardiovasc Electrophysiol. 1994 ; 5(11): 964-981
34. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation. 1995 ; 92 (9). 2550-2557
35. Connolly SJ, Hoffert DL.. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol. 1989 ; 63 (12). 817-819 (Pubitemid 19094222)
36. Lee SH, Chen SA, Chiang CE, et al. Comparisons of oral propafenone and quinidine as initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med. 1996 ; 239 (3). 253-260 (Pubitemid 26071359)
37. Reimold SC, Cantillion CO, Friedman PL, Antman EM.. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993 ; 71 (7). 558-563 (Pubitemid 23065009)
38. Pritchett EL, Page RL, Carlson M, Undesser K, Fava G.. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol. 2003 ; 92 (8). 941-946 (Pubitemid 37214806)
39. Meinertz T, Lip GY, Lombardi F, et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol. 2002 ; 90 (12). 1300-1306 (Pubitemid 35449474)
40. Grant AO.. Propafenone: an effective agent for the management of supraventricular arrhythmias. J Cardiovasc Electrophysiol. 1996 ; 7 (4). 353-364 (Pubitemid 26115954)
41. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000 ; 342 (13). 913-920 (Pubitemid 30177051)
42. Zimetbaum P.. Amiodarone for atrial fibrillation. N Engl J Med. 2007 ; 356 (9). 935-941
43. Huster TH, Pinto DS, Josephson ME, Zimetbaum P.. Early recurrence of arrhythmia in patients taking amiodarone or class IC agents for treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 2004 ; 93(9): 1173-1176 (Pubitemid 38521054)
44. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN.. Arrhythmias, drugs and defibrillations: frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation. 1993 ; 98: 1063-71 (Pubitemid 23264023)
45. Kaufman ES, Zimmerman PA, Wang T, et al. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study: a multivariate analysis. J Am Coll Cardiol. 2004 ; 44 (6). 1276-1282 (Pubitemid 39208885)
46. Pearce EN, Farwell AP, Braverman LE.. Thyroiditis. N Engl J Med. 2003 ; 348 (26). 2646-2655 (Pubitemid 36741593)
47. McClellan KJ, Markham A.. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. Drugs. 1999 ; 58 (6). 1043-1059 (Pubitemid 30055046)
48. Greenbaum RA, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study [abstract]. Circulation. 1998 ; 98(suppl 17): I - 633
49. Singh SN, Berk MR, Yellen LG, et al. Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: a multicenter study [abstract]. J Am Coll Cardiol. 1998 ; 31 (Suppl. 2A). 369A - 370A
50. Pedersen OD.. Dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function [abstract]. Eur Heart J. 1998 ; 19 (Abstr. Suppl). 363
51. FDC Pink Sheet. 1999 ; 61: 3-5
52. Anderson JL, Prystowsky EN.. Sotalol: an important new antiarrhythmic. Am Heart J. 1999 ; 137 (3). 388-409 (Pubitemid 29124104)
53. Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter.d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999 ; 84 (3). 270-277 (Pubitemid 29365121)
54. Wanless RS, Anderson K, Joy M, Joseph SP.. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997 ; 133 (4). 441-446 (Pubitemid 27188464)
55. Julian DG, Jackson FS, Szekely P, Prescott RJ.. A controlled trial of sotalol for 1 year after myocardial infarction. Circulation. 1983 ; 67 (6 Pt 2). I61 - I62
56. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH.. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003 ; 24 (16). 1481-1487 (Pubitemid 37010577)
57. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 ; 357 (10). 987-999 (Pubitemid 47367078)
58. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 ; 360 (7). 668-678
59. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008 ; 156 (3). 527 e1-9
60. Zimetbaum PJ.. Dronedarone for atrial fibrillation-an odyssey. N Engl J Med. 2009 ; 360 (18). 1811-1813
61. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation for the European Society of Cardiology (ESC). Eur Heart J. 2010 ; 31 (19). 2369-2429
62. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow up. Europace. 2007 ; 9 (6). 335-379
63. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010 ; 303 (4). 333-40
64. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 (12). 1139-1151
65. Kumar K, Zimetbaum PJ.. New and emerging antiarrhythmic drugs for atrial fibrillation: what may become available to the clinician in the near future. Curr Treat Options Cardiovasc Med. 2009 ; 11 (5). 373-380
66. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double blind, cross over study of flecainide and placebo with transtelephonic monitoring. Circulation. 1989 ; 80(6): 1557-1570 (Pubitemid 20031684)
67. Pietersen AH, Hellemann H.. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol. 1991 ; 67 (8). 713-717
68. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL.. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter [published erratum appears in J Am Coll Cardiol. 1989;13:264]. J Am Coll Cardiol. 1988 ; 12 (4). 1005-1111
69. Lee SH, Chen SA, Chiang CE, et al. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med. 1996 ; 239 (3). 253-260 (Pubitemid 26071359)
70. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 ; 357: 987-999 (Pubitemid 47367078)